Immuno-Oncology

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early

Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab

Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial

Immunotherapies made headlines in oncology last month when the Centers for Medicare & Medicaid Services (CMS) decided that the anticancer vaccine sipuleucel-T (Provenge) will be a payable expense for prostate cancer.

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dana Monroe from San Francisco Oncology Associates Discusses Ipilimumab's Side Effects

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process

Juanita Madison from Seattle Cancer Care Alliance Describes the Provenge Treatment Process

Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

As immunotherapy options grow, oncologists will need new frameworks of reference for evaluating whether patients are benefiting from the treatments